The academic publishing system: You pay to publish. You pay to read. You review for free. You are grateful to review. You are grateful to publish. Publishers swim in money. Sounds insane right, some might even say corrupt!? But it's true.

Just one week away!!!! 🙌🏽🙌🏽 All new incoming PHO fellows are welcome to register ✅ to our boot camp series where we’ll discuss common topics you’ll encounter as a first year PHO fellow 🫶. We are so excited to welcome you all to our community and can’t wait to meet you all ‼️

The ISTH Guidelines on haemophilia have just been published together with 3 commentaries on the eve of #ISTH2024. These have already raised very significant concerns with many in the community including WFH EHC_Haemophilia , PedNet, the haemophilia treaters from 1/15

🎉🎉

SCI-HUB 😎 #SciHub

It is time for one of the most famous slides in #hemophilia to be updated. Paper in JTH describes prospectively collected bleeding rate data in 825 children with mild hemophilia. tinyurl.com/yt4vvnes

Excited to start the Partners Physician Academy 2024! Partners Physician Academy

Today the 2024 #PartnersPhysicianAcademy began, covering hemophilia management and bleeding disorders care. The participants are ending their night with an interactive workshop on the principles of communication and leadership.

The painful personal story of Dr Keith Hoots’ experiences in the early days of the #HIV #AIDS epidemic is recounted at the #PartnersPhysicianAcademy.. Attendees gained appreciation on the challenges #hemophilia community faced. We must NEVER FORGET THE PAST!

It was truly one of the best professional opportunities that I have had as a junior faculty. Such an amazing group. If you are interested in hemostasis, definitely apply for the next Academy in the spring of 2025! #PartnersPhysicianAcademy

Although the American guidelines are in sync with other countries, treatment of pediatric ITP in the US is still quite aggressive with an overuse of IVIg in real world scenarios

In the field of inherited bleeding disorders, there are only two truly orphan diseases where we have no dedicated treatment for them. Hemophilia B with inhibitors and Factor V deficiency. With the announcement today that concizumab (Alhemo) will be approved for hemophilia B with

More true today than ever.

Going up! Talking all things networking and elevator pitches with Joanna Pierro for #ASHMEI in preparation for the ASH #ASH2024 annual meeting

The WFH supports the findings of 49 global experts that examined the ISTH Guidelines & published a critical appraisal in Haemophilia Journal. The appraisal highlights issues in the ISTH publication that could impact health outcomes for people with hemophilia: bit.ly/4g1zP70

Top notch science, meeting old friends and enjoying this #SoCal vibe at #ASH24 ASH

The PINES3 ITP data presented by Dr Shimano studying the use of upfront eltrombopag in pediatric ITP at #ASH24 The trial was closed EARLY - significantly higher efficacy and response in the eltrombopag arm compared to standard first line therapies! PDSA ITP SUPPORT ASH

The Issues with Health Insurance Companies, Explained by Doctors | WSJ youtu.be/0zV9qk5rIaM?si… via YouTube

A new study this week nature showed how the most common blood test performed—the CBC, complete blood count—contains a treasure chest of information that we are missing in reporting out to patients and doctors. Reviewed in the new Ground Truths, link in profile

Second patient this week with bleeding disorder. Prescribed TXA which is considered standard of care to control bleeding for ALL patients but it was rejected by Insurance because of ‘gender’. They said that it is only indicated for women 🤯 #priorauth #insurance